Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) (EMPIRE)

30 oktober 2019 bijgewerkt door: Paul Emery, University of Leeds

A Multicentre Randomised Trial Of Etanercept And Methotrexate To Induce Remission In Early Inflammatory Arthritis

TRIAL DESIGN

  1. Description This is a 18-month, double-blind, randomized, multicentre, outpatient study. The approximate duration of subject participation will be 18 months and the approximate total duration of the study will be 42 months. The duration of subject enrollment will be approximately 24 months.
  2. Discussion of Trial Design The study is designed to directly compare the effectiveness of combination therapy with MTX + ETN versus
  3. Principal research question/objective To determine the number of patients in clinical remission at 12 months of follow-up, as defined as the absence of symptoms and signs of inflammatory arthritis.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Early arthritis is frequently undifferentiated. It is well recognised that a substantial proportion of patients with an undifferentiated inflammatory arthritis will go on to develop persistent synovitis, with the strongest predictor of persistence being disease duration > 12 weeks (1-4). Studies have shown that patients with early oligoarthritis who fail to respond within 2 weeks to corticosteroid injections have a high likelihood of persistent disease (2). It is therefore clear that these patients with early inflammatory arthritis need definitive treatment, but the optimal therapeutic strategy is yet to be determined.

Tumor Necrosis Factor (TNF) is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important role in the inflammatory process of rheumatoid and other arthritis, and the resulting joint pathology. Elevated levels of TNF are found in the synovial fluid of patients with RA. Two distinct receptors for TNF exist naturally as monomeric molecules on the cell surfaces and in soluble forms. Biological activity of TNF is dependent upon binding to either cell surface TNF receptors (TNFR). Etanercept (ETN) is a dimeric fusion protein consisting of the p75 TNFR linked to the Fc portion of human IgG1, and is capable of binding two TNF molecules. Etanercept inhibits binding of both TNF-alpha and TNF-beta to cell surface TNFRs, rendering TNF biologically inactive. Agents that block TNF are effective in all types of arthritis (with the exclusion of connective tissue diseases).

It is generally agreed that there is a window of opportunity in active early inflammatory arthritis in which definitive treatment may give a disproportionate improvement compared to treatment at a later time, and may well be able to induce remission in a subgroup of patients.

Studies in early rheumatoid arthritis (< 12 months) have shown that remission-induction with the TNF-antagonist infliximab provides a significant reduction in MRI-evidence of synovitis and erosions at 12 months with evidence of sustained functional and quality of life benefits at 2 years, despite withdrawal of infliximab at 12 months (5). Results from the TEMPO study show that treatment of established rheumatoid arthritis with ETN+MTX achieves remission in about 40% patients (6). TNF antagonists also have the therapeutic benefit of rapid and sustained suppression of inflammation.

Treatment of patients with early undifferentiated arthritis with ETN+MTX is hypothesised to prevent progression of persistent disabling disease in a significant number of patients. Induction of remission at this time in the disease course may result in sustained remission, reduce the need for further treatment, and be most cost effective therapeutic strategy.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

112

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Verenigd Koninkrijk
    • West Yorkshire
      • Leeds, West Yorkshire, Verenigd Koninkrijk, LS7 4SA
        • Leeds Teaching Hospital HNS Trust

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Is age 18 -80 years old
  • Patients have articular synovitis, within 3 months of diagnosis
  • Either RF antibody (+) or anti-CCP antibody (+) or SE (+)
  • Demonstrates a negative urine pregnancy test at screening if female of childbearing potential
  • Agrees to use a medically accepted form of contraception during the study and for 3 months after the last dose of study drug, if sexually active male
  • Is capable of understanding and signing an informed consent form
  • Is able and willing to self-inject study drug or have a designee who can do so
  • Is able and willing to take oral medication
  • Is able to store injectable test article at 2° C to 8° C
  • Demonstrates a negative tuberculosis screening test

Exclusion Criteria:

  • Received previous treatment with any DMARDS
  • Received previous treatment with ETN or other tumour necrosis factor (TNF) antagonist (e.g. a TNF monoclonal antibody or a soluble TNF-receptor)
  • Previous treatment with IL-1 receptor antagonist
  • Chronic arthritis diagnosed before 16 years old
  • Received any investigational "biological" agent within 3 months of screening visit
  • Received treatment with any investigational drug of "chemical" nature within one month prior to study screening
  • Known Human Immunodeficiency Virus (HIV)
  • Presence of any contraindication to ETN or MTX
  • Has significant concurrent medical diseases
  • Has cancer or a history of cancer within 5 years of entering the screening period
  • Current crystal or infective arthritis
  • Chronic infection of the upper respiratory tract, chest, urinary tract or skin
  • Any ongoing or active infection or any major episode of infection requiring hospitalization or treatment with IV antibiotics within the preceding 30 days and/or orally administered antibiotics in the preceding 15 days
  • Demonstrates liver function abnormality
  • Has renal disease
  • Has leukopenia
  • Has thrombocytopenia
  • Has a hemoglobin level of < 9g/L for males and < 85 g/L for females
  • Is pregnant or breast-feeding
  • Joint surgery within preceding 2 months (at joints to be assessed within this study)
  • Received anti-CD4, diphtheria interleukin-2 fusion protein, anti-interleukin-6 (anti-IL-6), rituximab or other immunosuppressive biologic during the last 6 months before screening, and treatment with such agents more than 6 months before screening if there are persistent signs of immunosuppression (with a subsequent abnormal absolute T-cell count) at screening visit
  • Received any live (attenuated) vaccines within 4 weeks of screening visit
  • Received cyclophosphamide within 6 months of screening visit
  • Any corticosteroids within 28days prior to screening
  • Uses a dose of NSAID greater than the maximum recommended dose in the product information at the screening visit
  • Has a history of confirmed blood dyscrasia
  • Has any condition judged by the physician to cause this study to be detrimental to the subject
  • Has a history of drug abuse or psychiatric disease that would interfere with the ability to comply with the study protocol
  • Has a history of alcohol abuse or excessive alcohol beverage consumption
  • Has a history of known liver cirrhosis, fibrosis, or fatty liver
  • Has a history of any viral hepatitis within 1 year of screening

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Combination Therapy
Methotrexate & Etanercept
Geneesmiddel: Etanercept (ETN)
ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
Andere namen:
  • Enbrel
Placebo-vergelijker: Single-agent therapy
Methotrexate (MTX)
Geneesmiddel: Placebo
ETN-matching placebo SC injections once weekly and MTX orally once weekly.
Andere namen:
  • Maxtrex

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
clinical remission
Tijdsspanne: 12 months
To determine the number of patients in clinical remission at 12 months, as defined as the absence of symptoms and signs of inflammatory arthritis (i.e. swollen joint count 0; tender joint count 0)
12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
clinical remission
Tijdsspanne: 18 months
The number of patients in clinical remission at 18 months (as defined as absence of symptoms and signs of clinical arthritis i.e. swollen joint count 0 ; tender joint count 0)
18 months
Conventional disease activity measures
Tijdsspanne: week 78
Conventional disease activity measures (VAS pain/fatigue/global/physician, EMS, TJC, SJC, CRP, ESR)
week 78
Functional, work and quality of life assessments
Tijdsspanne: Week 78
Functional, work and quality of life assessments (HAQ, WIS, WDA, EQ-5d, SF-36)
Week 78
remission
Tijdsspanne: Week 26
Proportion of patients achieving 26 weeks of remission
Week 26
DAS 44
Tijdsspanne: Week 78
Disease Activity Score (DAS) 44
Week 78
drug-free remission
Tijdsspanne: 12 & 18 mths
The number of patients in drug-free remission at 12 18 months
12 & 18 mths
etanercept-free remission
Tijdsspanne: 12 and 18 months
The number of patients in etanercept-free remission at 12 and 18 months (ETN arm)
12 and 18 months
Remission by ACR Criteria
Tijdsspanne: Week 78
Remission by ACR Criteria
Week 78
effects of the combination of ETN and MTX to MTX alone on radiographic change
Tijdsspanne: 12 months and 18 months
To compare the effects of the combination of ETN and MTX to MTX alone on radiographic change at 12 months and 18 months
12 months and 18 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

University of Leeds

Onderzoekers

  • Hoofdonderzoeker: Paul Emery, Prof, University of Leeds

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 september 2006

Primaire voltooiing (Werkelijk)

5 november 2010

Studie voltooiing (Werkelijk)

5 november 2010

Studieregistratiedata

Eerst ingediend

24 februari 2011

Eerst ingediend dat voldeed aan de QC-criteria

24 februari 2011

Eerst geplaatst (Schatting)

25 februari 2011

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 november 2019

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2019

Laatst geverifieerd

1 oktober 2019

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • RR05/7150
  • 2005-005467-29 (EudraCT-nummer)

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren